Gufic BioScience (GUFICBIO)

FairStock Score: 16/100 — RISKY

Score breakdown: P/E: 0/3 · ROCE: 1/2 · Growth: 0/2 · Dividend: 0/1

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I am a value investor first, so I ask whether ₹422.20 for Gufic BioScience gives me a bargain or a hope. The company has real growth: sales up 14.69%, profit up 86.03%, and five-year revenue CAGR of 14.01%. That is a fast-growing pharma business. Latest quarter sales of ₹231 Cr and net profit of ₹12 Cr show it is profitable, but margin is thin—about 5%—so I want durable pricing power and not one-off gains. Promoter holding of 72.50% aligns incentives, and debt/equity of 0.61 is not reckless, though not fortress-like. ROCE of 13.15% and ROE of 8.80% tell me the business earns modest returns on capital; a wonderful business should do better. The biggest issue is price. At P/E 65.76 and P/B 6.38, I am paying a huge premium for that growth. Book value is ₹66.20, so the stock trades far above asset value. PEG of 4.99 says growth is not cheap. Dividend yield of 0.02% gives almost no cash return. Piotroski F-Score of 4/9 and FairStock Score of 16/100 (risky) support caution. Graham would demand a margin of safety; I see little. Buffett would ask if the moat is durable; low ROE and high valuation suggest it is not proven. The 52-week range ₹268–₹466.05 shows volatility and near-high price. I would wait for either profit consistency, ROCE/ROE improvement, debt reduction, or a much lower price. Until then, this is a speculative fast grower, not a value purchase.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer